Emerging evidence · Grade B
VIP
Vasoactive Intestinal Peptide (VIP)
Score
60 / 100
Class
Anti-inflammatory neuropeptide
Drug form
Aviptadil
Status
Investigational (uses unproven)
TL;DR
01
Vasoactive Intestinal Peptide is a 28-amino-acid signaling molecule with genuine, potent anti-inflammatory biology in the gut, lungs, and immune system.
02
Its synthetic form (aviptadil) was trialed at scale for COVID-19 respiratory failure — but those trials did not clearly succeed, and it did not gain approval for that use.
03
Its popularized use as an intranasal spray for 'chronic inflammatory response syndrome' (mold illness / CIRS) rests on case reports and a fringe protocol, not controlled trials.
04
So VIP has real biology and reached serious clinical testing, but its marketed consumer uses are weakly supported.
05
Nasal/consumer VIP is compounded or research-grade and not an approved therapy for these uses.
Anti-inflammatory biology
Real / potent
gut, lung, immune
Aviptadil for ARDS
Inconclusive
no approval for COVID
CIRS / mold-illness use
Case reports only
fringe protocol
Controlled evidence (consumer use)
Lacking
for nasal VIP
Approval
None (these uses)
compounded/research
Part 01 · How it works
Mechanism.
VIP is a natural signaling peptide that calms inflammation across the gut, lungs, and immune system — real and potent biology. Because of that, its synthetic version (aviptadil) was put through large trials for COVID-19 lung failure; the results were not clearly positive and it wasn't approved for that. Separately, VIP nasal spray became popular in 'mold illness' / CIRS circles, but that use is based on a fringe protocol and case reports rather than controlled trials. In short: the underlying biology is legitimate, but the specific ways VIP is sold and used to consumers aren't backed by solid evidence.
A real anti-inflammatory signal that flunked its big lung-failure audition and whose trendy nasal-spray use rests on anecdotes — legitimate biology, unproven applications.
VPAC receptor signaling
Acts via VPAC1/VPAC2 receptors to suppress pro-inflammatory cytokines and promote regulatory immune responses.
Pulmonary/vasoactive effects
Vasodilatory and cytoprotective in lung tissue — the rationale for aviptadil in ARDS.
Aviptadil trials
Large COVID-19 ARDS trials did not clearly demonstrate benefit; no approval for that indication.
Evidence stage
Real biology; inconclusive ARDS trials; consumer CIRS/nasal use rests on case reports.
Part 02 · Dosing & administration
How it's taken.
Community-reported · unregulatedValues below reflect commonly reported community protocols for VIP. These are anecdotal and unregulated — not clinically validated and not a recommendation. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.
Standard dose
50 mcg per intranasal spray
Intranasal (compounded nasal spray) · 1 spray 4×/day (~200 mcg/day); range 1–8 sprays/day, titrated
Duration
Months; tapered toward the minimum effective dose per CIRS protocol
·
In the Shoemaker CIRS protocol, VIP is the last of 12 steps — begun only after removal from water-damaged-building exposure, eradication of MARCoNS (negative deep-nasal culture, typically via BEG/EDTA spray), and correction of other CIRS labs.
·
Reported clinical use: 50 mcg per spray, ~4 sprays/day, with a first-dose in-office blood-pressure and serum-lipase check because VIP is vasodilatory (flushing, hypotension) and can affect the pancreas.
·
Compounded nasal VIP is not FDA-approved for CIRS; the evidence base is largely one practitioner group’s case series, and IV aviptadil trial dosing is not interchangeable with nasal VIP.
Need help with reconstitution?
Use the free peptide calculator for dilution, unit conversion, and injection volume.
Part 03 · Safety
Side effects, rare serious events, who shouldn't.
Common
Flushing
Vasodilatory effect.
Common (systemic)
Hypotension / palpitations
From vasodilation.
Systemic dosing
Nasal irritation
For intranasal formulations.
Nasal use
Serious · rare
Blood-pressure effects
Potent vasodilator; caution with systemic dosing.
Systemic
Product-quality risk
Compounded/research supply may not match labeled purity/dose.
Source-dependent
Absolute · do not use
×
Pregnancy or breastfeeding
×
Children under 18
×
Known hypersensitivity to VIP or any component
×
Severe hypotension (VIP is a potent vasodilator)
×
History of diarrheal disorders (VIP stimulates intestinal secretion)
Relative · discuss first
!
Hypotension or cardiovascular instability — vasodilatory effects
!
Reliance on it for 'CIRS/mold illness' as proven — evidence is case-report level
!
Pregnancy or breastfeeding — insufficient data
!
Anyone expecting a proven consumer benefit — the marketed uses are unproven
Interactions
Antihypertensives
VIP is a potent vasodilator; additive hypotensive effect may cause symptomatic hypotension
Major
PDE5 inhibitors (sildenafil, tadalafil)
Additive vasodilation; significant risk of hypotension
Major
Corticosteroids
VIP has inflammation-modulating properties; may potentiate or interfere with corticosteroid effects depending on context
Moderate
Immunosuppressants
VIP modulates immune function (promotes regulatory T-cells); may have additive immunosuppressive effects
Moderate
Labs to monitor
Blood Pressure
Before and after each dose initially
VIP is a potent vasodilator — hypotension risk
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
Liver and kidney function
CRP / ESR
Baseline and monthly
Inflammation-modulating effects monitoring
CBC with Differential
Baseline and every 3 months
Immune modulation monitoring
TGF-beta, C4a, MSH (Shoemaker Panel)
Per CIRS protocol
If used for CIRS/mold illness protocol
Part 04 · Evidence
How strong is the evidence?
60
Grade B
Grade B, Emerging. VIP has legitimate, potent anti-inflammatory biology and reached large clinical trials as aviptadil — but those did not clearly succeed, and its popular consumer uses (nasal VIP for CIRS/mold illness) rest on case reports rather than controlled evidence.
Mechanistic plausibility
Well-established anti-inflammatory/vasoactive biology.
78
Human evidence
Large aviptadil ARDS trials were inconclusive; consumer uses are case-report level.
50
Safety & tolerability
Vasodilatory effects (flushing, hypotension) with systemic dosing; nasal use less characterized.
60
Durability
No durable controlled-outcome evidence for the marketed uses.
52
Independence
Legitimate independent research on the peptide; the CIRS use is a single-protocol niche.
58
Part 05 · Research log
Every study we cite.
We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.
01
2016
Am J Case Rep Flagged
VIP replacement in a complex CIRS/biotoxin case (case report)
A patient with refractory ulcerative colitis and chronic fatigue attributed to mold/biotoxin exposure improved after multiple interventions including VIP replacement — illustrative of the CIRS use, but a single uncontrolled case among many co-interventions.
Single case report (multi-intervention) · n = 1 · One patient, many simultaneous interventions; cannot attribute benefit to VIP.
PMID 27165859 ↗
Very low (case report)
Evidence against
What didn't work, and where the evidence is thin.
Every publication is incentivized to tell you a peptide works. We catalogue the null results, failed trials, and mechanism limits we found in the same literature — so you can weigh them against the upside, with your provider.
01
Consumer uses rest on case reports; the big trial didn't clearly work
Null result Am J Case Rep · 2016
VIP's popular nasal use for 'CIRS'/mold illness is supported only by case reports within a fringe protocol, and the large aviptadil trials for COVID-19 respiratory failure did not clearly demonstrate benefit or achieve approval.
What this means: Legitimate anti-inflammatory biology has not translated into proven consumer benefit. The marketed uses are unproven.
PMID 27165859 ↗
Part 06 · Cost & access
Where it's available, at what price.
United States
Not approved (these uses)
Aviptadil investigational; nasal VIP compounded off-protocol. Not approved for CIRS or general anti-inflammatory use.
Compounded / grey-market
European Union
Not approved (these uses)
No approved consumer indication.
N/A
United Kingdom
Not approved (these uses)
No approved consumer indication.
N/A
Canada
Not approved (these uses)
No approved consumer indication.
N/A
The Peptide Column takes no affiliate commission from any source. VIP has real anti-inflammatory biology, but its marketed consumer uses (nasal VIP for CIRS/mold illness) are unproven and its aviptadil ARDS trials were inconclusive; consumer supply is compounded/research-grade. We link only to clinician-directed care, never to sellers.
Part 07 · Your appointment
Questions to bring.
01
Have my VIP levels been measured, and does low VIP fit within a CIRS diagnosis framework?
02
Should VIP be used only after completing the Shoemaker Protocol (removal, binders, etc.) or earlier?
03
Are there risks to intranasal VIP administration, particularly with regard to cardiovascular effects?
04
Is compounded intranasal VIP available through a licensed compounding pharmacy, and what is the appropriate oversight?
References
Every citation, numbered.
Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.
- 01. VIP replacement in a complex CIRS/biotoxin case (case report) · Am J Case Rep, 2016 · PMID 27165859 ↗
- 02. ClinicalTrials.gov. Aviptadil (VIP) COVID-19 ARDS trials